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Abstract
Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves 
pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and 
are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological thera-
pies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, 
synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) 
are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD 
studies have demonstrated some promising therapies but also provided new considerations for future trials.
Keywords Osteoarthritis · Nociceptive pain · DMOAD · Cartilage · Inflammation · Synovitis
Introduction
Osteoarthritis (OA) is a chronic, painful arthritis and a major 
cause of disability in affected individuals. At least 242 mil-
lion people globally have hip/knee OA [1]. In addition, with 
an ageing population and rising risk factors such as obesity, 
this prevalence is growing [2]. As a result of the disabil-
ity caused by OA, there is a significant cost to the global 
economy [3]. The pathogenesis of OA is complex with 
mechanical, genetic, metabolic and inflammatory pathways 
involved in its slowly evolving process [4]. Structure–pain 
relationships remain difficult to understand, and at the indi-
vidual patient level, it is unclear which structures may be 
contributing to pain. Intra-articular candidates include bone 
and synovium, though it is worth noting that the amount of 
pain that pathologies in these tissues explain is small [5], 
and extra-articular features (e.g. tendinitis and bursitis) may 
confound associations.
OA management entails pharmacological and non-phar-
macological approaches; when these fail to relieve symp-
toms, joint replacement surgery is considered. Non-phar-
macological options (especially muscle strengthening) are 
often underutilised, and pharmacological options have not 
progressed significantly for decades: primarily paracetamol, 
non-steroidal anti-inflammatory drugs (NSAIDs, topical and 
oral) and opioids. However, the beneficial effect of paraceta-
mol and opioids are limited, while NSAIDs and opioids are 
unsuitable for many patients because of their side-effects 
[6]. Intra-articular therapy, including corticosteroids, may 
also be used, although their effects tend to be short-lived.
This narrative review will update clinicians with recent 
developments on the use of existing pharmacological 
therapies and discuss novel treatments currently under an 
advanced stage of investigation (at least in phase II tri-
als) for the treatment of OA. The therapies discussed have 
mostly been investigated for the treatment of knee OA and 
less commonly in hand OA. We have attempted to catego-
rise these agents according to the tissues they target: bone 
and cartilage, nerves and synovium (the latter categorised as 
“immunomodulators”); we have included studies with both 
symptom and structural outcomes.
Though not systematic, this review was based on a 
PubMed search and review of meeting abstracts on trials 
reported between 2017 and 2019; both positive and negative 
reporting trials were included. We have excluded non-phar-
macological treatments, therapies marketed as devices (e.g. 
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hyaluronans) and nutraceuticals (e.g. glucosamine). Where 
relevant, older studies have been referenced to give context 
on the candidate therapy.
Targeting Bone and Cartilage
Bisphosphonates
Subchondral bone plays a role in maintaining hyaline articu-
lar cartilage integrity and its pathology is integral to the OA 
process [7]. A number of therapies used for osteoporosis 
have been explored as OA therapies, targeting altered bone 
turnover in the subchondral region [8, 9]. Bisphosphonates 
have a long history of trials in OA, where they are thought to 
have a protective effect on subchondral bone and cartilage. 
A recent meta-analysis failed to demonstrate symptomatic 
improvement or reduction in radiographic OA progres-
sion with bisphosphonate therapy (Table 1) [10]. However, 
reduced MRI BML size was demonstrated in two studies. It 
is likely that many of the studies assessing radiographic pro-
gression were underpowered and many did not use modern 
inclusion criteria that enable detection of a pain response 
(such as pain > 4- on a 10-point scale).
Recent studies have focused recruitment on patients with 
definite subchondral bone abnormalities, specifically MRI-
detected bone marrow lesions (BMLs). BMLs are commonly 
seen on MRI scans of OA knees, represent areas of trabecu-
lar loss, microfracture and fibrosis, and have associations 
with both pain and progressive cartilage loss [16–19]. Zole-
dronic acid (ZA) was compared with placebo in a double-
blind, parallel-group trial of 59 patients aged 50–80 with 
knee pain and at least one BML on MRI [13]. Results were 
promising, demonstrating a significant symptomatic benefit 
and reduction in BML size at 6 months. The preliminary 
report from the larger follow-up multicentre, randomised 
controlled trial has been recently presented. In this study, 
223 knee OA patients with significant knee pain and MRI-
detected BMLs received annual intravenous infusion of 
ZA 5 mg or placebo over 2 years [20]. Unfortunately, no 
significant improvement was detected at 24 months in the 
Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) pain scale, WOMAC function scale, or 
BML size change with ZA.
A sub-study of this 2-year ZA trial investigated the 
effects of ZA 5 mg plus intravenous methylprednisolone 
10 mg in a preparation called  VOLT0117. 117 patients with 
symptomatic knee OA were randomised to receive single 
dose VOLT01, ZA 5 mg monotherapy or placebo. The 
study’s primary outcome measurement was the incidence 
of the acute phase response following ZA administration (a 
flu-like or febrile response which can occur following IV 
bisphosphonate) and secondary outcomes measured BML 
size, WOMAC and visual analogue scale (VAS) pain and 
WOMAC function at 6 months. The incidence of acute 
phase responses was similar between treatment groups. In 
addition, VOLT01 and ZA were not superior to placebo in 
any of the secondary outcome pain measurements.
Summary
Recent studies have failed to demonstrate structural or symp-
tomatic improvement with bisphosphonates in knee OA.
Strontium Ranelate
Strontium ranelate has also been trialled in knee OA. The 
SEKOIA trial investigated strontium 1 or 2 g/day versus pla-
cebo in a randomised, double-blind, 36-month study involv-
ing 1683 patients with symptomatic primary knee OA [21]. 
A significant reduction in radiographic joint space width 
(JSW; a surrogate for hyaline cartilage loss) reduction with 
both strontium doses compared to placebo was demonstrated 
at 36 months. The results also demonstrated a significant 
improvement in WOMAC total score and pain subscore 
at 2 g/day, though the effect size was very small (approxi-
mately 0.1). However, with a 14% annualised dropout rate, 
participant retention in (much desired) long-term OA trials 
is difficult and handling consequent missing data remains a 
complex issue. Strontium is also contraindicated in cardio-
vascular disease—a co-morbid condition patients with OA 
are also at increased risk of developing [22].
Summary
Strontium may improve pain and structural progression in 
knee OA but the benefits are small, and given potential car-
diovascular risk, its use as a treatment is unlikely.
Sprifermin
Animal models of OA have demonstrated that fibroblast 
growth factor-18 can increase cartilage volume via pro-
liferation of chondrocytes and modulating extracellular 
matrix turnover [23, 24]. Sprifermin is a recombinant 
human fibroblast growth factor-18 (rhFGF18) which is 
administered intra-articularly and targets FGFR3 recep-
tors in cartilage [25]. Sprifermin was investigated in a 
phase I, 1-year, randomised, double‐blind, placebo‐con-
trolled, proof‐of‐concept trial at doses of 10 μg, 30 μg, 
and 100 μg [26]. Subjects received 2 cycles of three once-
weekly injections (at weeks 0–2 and 13–15) of sprifermin 
or placebo and the results from 168 patients were evalu-
ated. Although sprifermin failed to achieve its primary 
efficacy endpoint of significant reduction in loss of cen-
tral medial femorotibial compartment cartilage thickness 
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at 6 or 12 months, the study did, however, achieve its pre-
specified (and more sensitive) secondary structural effi-
cacy MRI endpoints: significant reductions in loss of total 
femorotibial and lateral femorotibial cartilage thickness.
A further 5-year Phase II, dose-ranging, randomised 
trial of sprifermin (the FORWARD trial) is currently 
ongoing [27]. 549 patients were randomised to 1 of 5 
groups: intra-articular injections of 100 microg of spri-
fermin administered 6-monthly (n = 110) or 12-monthly 
(n = 110); 30 microg of sprifermin 6-monthly (n = 111) 
or 12-monthly (n = 110); or placebo every 6  months 
(n = 108). Each treatment cycle consisted of 3 once-
weekly injections and total treatment duration was 
18  months. Structural endpoints (cartilage thickness) 
were measured by quantitative MRI at the tibiofemoral 
joint. There was an initial dose-dependent increase in 
overall cartilage thickness with sprifermin 100 μg for 
the first 2 years, though no significant improvement in 
WOMAC total score and pain, function, and stiffness sub-
scale scores were detected between any of the treatment 
groups and placebo at 2 years [27].
Overall cartilage thickness reduced for all treatment 
groups between years 2 and 3 although the significant dif-
ference between sprifermin 100 μg 6-monthly and placebo 
groups was maintained [28]. The loss of cartilage during 
the period may reflect the cessation of treatment. Pre-
liminary results at 3 years also demonstrated a reduction 
in the expected (natural history) mean cartilage thickness 
loss from baseline to 3 years in patients on Sprifermin 
100 μg 6-monthly versus placebo at the total femoroti-
bial joint, and in the medial, lateral, central medial and 
central-lateral sub-regions. 18.4% (sprifermin) and 24.1% 
(placebo) of participants discontinued the study within 
3 years. At year 3 there was also no difference in symp-
tom improvement between treatment groups, raising an 
important question regarding treatments improving OA 
structural pathologies: how long after structural change 
should patients be monitored in order to detect a differ-
ence in patient important outcomes (such as reduction in 
symptoms or joint replacement)?
The FORWARD study was primarily designed to 
assess structural progression and did not use modern 
pain trial inclusion criteria. Preliminary data from a post 
hoc analysis at year 3 of an ‘at-risk’ subgroup of patients 
with higher pain scores (WOMAC pain score of 40–90) 
and lower joint space width (1.5–3.5 mm) at baseline—
which are both predictors of more responsive outcome 
measurement—reported that patients with reduced medial 
or lateral joint space width at baseline along with higher 
baseline pain scores had significantly greater WOMAC 
pain score improvements with the highest dose of spri-
fermin (100 μg 6-monthly) compared with placebo [29].
Summary
Sprifermin has demonstrated structural improvement in knee 
OA compared to placebo. Translation into symptomatic 
improvements is less certain and phase III trials are awaited.
Wnt Pathway Inhibition
The Wnt signalling pathway is a signal transduction pathway 
implicated in cartilage breakdown and OA pathophysiology, 
through its effect on chondrocyte, osteoblast and synovial 
cell differentiation [30, 31]. Altered expression of genes 
encoding Wnt signalling pathway proteins have been dem-
onstrated in murine and human OA tissues, along with lower 
levels of the Wnt inhibitory protein DKK1 [31]. Lorecivivint 
(formerly SM04690) is an inhibitor of the Wnt signalling 
pathway and also inhibits the enzymes CDC-like kinase 2 
(CLK2) and dual-specificity tyrosine phosphorylation-reg-
ulated kinase 1A, enhancing chondrogenesis, chondrocyte 
function and reducing inflammation [32]. It has been inves-
tigated in a phase IIa randomised, double-blind, placebo-
controlled trial comparing 3 doses (low, medium and high) 
in 455 patients with knee OA. No statistically significant 
improvement in WOMAC A1 pain (pain when walking on a 
flat surface) was demonstrated between treatment groups and 
placebo. Exploratory analyses investigated the hypothesis 
that patients with bilateral symptomatic knee OA would be 
less responsive to treatment than patients with only one knee 
affected (a ‘widespread pain’ interference phenomenon). 
Two pre-specified subpopulations were therefore defined: 
unilateral symptomatic knee OA (n = 164) and subjects 
with unilateral knee OA without widespread pain (n = 128). 
Medium dose (0.07 mg) SM04690 did significantly improve 
WOMAC A1 score versus placebo in unilateral symptomatic 
knee patients at 39 and 52 weeks and unilateral symptomatic 
patients without widespread pain at 26, 39 and 52 weeks 
[33]. Reduction in radiographic joint space width progres-
sion was also significantly greater in the 0.07 mg treatment 
group versus placebo at week 52, though patient numbers 
were small for structural assessment [34].
A further 24-week, phase IIb study randomised 695 
patients to receive a single dose lorecivivint (0.03, 0.07, 
0.15 or 0.23 mg), vehicle placebo or sham (dry needle only) 
at baseline. 635 subjects completed the study and the pre-
liminary results demonstrated significant improvements 
from baseline in 0.07 mg and 0.23 mg lorecivivint dose 
groups compared to placebo for numeric rating scale pain 
(0.07 mg and 0.23 mg at weeks 12 and week 24), WOMAC 
Pain (0.07 mg at week 12; 0.23 mg at weeks 12 and 24), 
WOMAC Physical Function (0.07 mg at week 12; 0.23 mg 
at weeks 12 and 24) and patient global assessment (0.07 mg 
at week 12; 0.23 mg at weeks 12 and 24) [35]. In addi-
tion, a homogenous group of patients with joint space width 
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2–4 mm and no widespread pain demonstrated an improved 
symptom effect size vs placebo at 12 and 24 weeks com-
pared to the full analysis set at 0.07 mg [36].
Summary
Sub-analyses of phase II trials suggest potential sympto-
matic and structural benefits with lorecivivint versus pla-
cebo. Await results of phase III trials which are underway.
Cathepsin K Inhibition
Cathepsin K is a cysteine protease highly expressed in acti-
vated osteoclasts. It plays an important role in bone resorp-
tion, degrading types I and II collagen and aggrecan found in 
cartilage. MIV-711 is a novel potent, selective and reversible 
inhibitor of cathepsin K which inhibits the actions of osteo-
clasts and is associated with reduced expression of biomark-
ers of bone resorption and cartilage loss [37]. Cathepsin K 
inhibition has also recently been shown to reduce the risk 
of fracture in post-menopausal osteoporosis, although with 
an increased cardiovascular risk [38]. A multicentre, ran-
domised, placebo-controlled, double-blind, three-arm paral-
lel, Phase IIa study evaluated the efficacy, safety and toler-
ability of MIV-711 in patients with knee OA [39]. Patients 
received oral MIV-711 100 mg, 200 mg or matched placebo 
once daily for 26 weeks. No significant difference in pain 
reduction and quality of life scores were detected, although 
there was a trend towards increased reduction in pain scores 
with 100 mg and 200 mg doses at 26 weeks. There was a 
significant reduction in femoral OA bone disease progres-
sion on MRI at week 26 for MIV-711 100 mg and 200 mg 
doses versus placebo and significant reduction in loss of 
cartilage thickness on the medial femur for 100 mg dose 
versus placebo. A unique aspect of this trial was the key sec-
ondary outcome measure of 3D quantitative bone area using 
a machine learning method, enabling detection of change 
in a relatively small-number OA trial; this novel imaging 
biomarker can potentially be used as an outcome measure 
in further DMOAD trials [40]. The main adverse events 
reported were musculoskeletal symptoms, skin disorders and 
infections, although there was a reported overall acceptable 
safety profile [41]. Further studies are required to evaluate 
the potential structure-modifying effects of this agent.
Summary
Cathepsin K reduced knee OA structural progression but no 
significant symptom improvement over placebo was demon-
strated over 6 months in a small phase II trial.
Targeting Nerves
As might be expected from this these modes of action these 
therapies are symptomatic and not trying to modify joint 
structure.
Intra‑articular Capsaicin
Capsaicin is a chilli pepper extract which binds to a protein 
called transient receptor potential cation channel subfamily 
V member 1 (TRPV1), which is expressed on nociceptive 
nerve fibres (Aδ and C). It causes the burning sensation asso-
ciated with chillies but is also considered an attractive target 
for potential analgesic medication, as its activation triggers 
a prolonged refractory state known as desensitisation [42]. 
CNTX-4975, the first intra-articular capsaicin preparation, is a 
highly purified, synthetic trans-capsaicin specifically targeting 
TRPV1-containing pain nociceptors [43]. Other sensory fibres 
such as touch or pressure are unaffected. Previous evidence 
supported topical capsaicin for relieving OA pain [44–47]. A 
phase II trial of single dose CNTX-4975 1 mg knee injec-
tion in patients with moderately painful knee OA was shown 
to improve the WOMAC A1 pain score (pain on walking) at 
weeks 12 and 24 in a 24-week, randomised, double-blind, 
placebo-controlled, dose-ranging study [48]. Data on adverse 
events are limited currently but the most common treatment-
emergent adverse event is reported to be post-procedural pain, 
although this greatly subsides by 2 h post injection; in addition, 
there were no withdrawals due to side-effects [48]. Phase III 
trials of CNTX-4975 and a study examining the efficacy of 
repeated doses are currently in progress [49, 50].
Summary
Intra-articular capsaicin has demonstrated symptom improve-
ment in knee OA. Phase III studies are in progress.
Anti‑nerve Growth Factor Monoclonal Antibodies
Nerve growth factor (NGF) is a neurotrophin that binds to 
TrkA and has increased expression in OA [51]. It stimulates 
the growth of nociceptive nerve fibres and expression of noci-
ceptive cell surface receptors. Osteoarthritic knee joints are 
highly innervated with nerve fibres in the joint capsule, liga-
ments, periosteum, menisci, subchondral bone and synovium 
[52]. This makes the peripheral nociceptive pathway an attrac-
tive target for novel analgesic agents.
Tanezumab
Tanezumab, and fasinumab are monoclonal antibodies 
targeting NGF, preventing it from binding its receptor to 
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reduce pain [53]. Tanezumab is a humanised IgG type 2 
monoclonal antibody produced by Pfizer and Eli Lilly 
with high specificity for NGF. Most data are available on 
tanezumab and in a meta-analysis of 9 studies with 10 
randomised controlled trials enrolling 7665 patients with 
knee or hip OA, intravenous tanezumab (2.5 mg, 5 mg and 
10 mg) demonstrated superior efficacy compared to pla-
cebo/active comparator (significantly improving WOMAC 
pain subscale, WOMAC function subscale and patient 
global assessment) [54].
Fears of joint safety due to reported cases of rapidly pro-
gressive OA (RPOA) and then fears about possible sympa-
thetic nerve problems (not borne out subsequently) meant 
this class of drugs underwent a number of regulatory holds, 
but are now back in development.
More recent studies have investigated subcutaneous 
(SC) preparations of tanezumab. A phase III trial of SC 
tanezumab compared fixed (2.5 mg) doses 8 weeks apart 
and step up dosing (2.5 mg administered at baseline, 5 mg 
administered at week 8) versus placebo in 696 OA hip/
knee patients who had not responded to, or unable to tol-
erate, standard analgesia. Tanezumab 2.5 mg fixed and 
2.5 mg/5 mg step up dosing was demonstrated to be superior 
to placebo in improving WOMAC Pain, WOMAC function 
and patient global assessment scores at week 16 [55]. There 
were more joint replacements observed in patients receiv-
ing tanezumab, although these were mostly elective and not 
associated with an AE. Two joint replacements were con-
sidered to be due to RPOA (see below).
Earlier phase III studies have demonstrated tanezumab 
monotherapy at 5 mg and 10 mg to have greater analge-
sic efficacy over NSAIDs (celecoxib 100 mg and naproxen 
500 mg) and oxycodone 10–40 mg [56, 57]. Combination 
tanezumab and NSAID therapy also demonstrated signifi-
cantly greater analgesic efficacy over NSAID monotherapy 
but not compared with tanezumab monotherapy [57]. A 
recent phase III study investigated SC tanezumab 2.5 mg or 
5 mg versus NSAID (naproxen 500 mg, celecoxib 100 mg, 
or diclofenac ER 75 mg orally) in an 80-week study of 2996 
patients with hip or knee OA. Tanezumab 5 mg significantly 
improved WOMAC pain and WOMAC function scores com-
pared to the NSAID group at week 16 but not the Patient’s 
Global Assessment of OA. There were no significant 
improvements compared to NSAID with tanezumab 2.5 mg 
at 16 weeks or with either tanezumab doses at 56 weeks 
[58].
Tanezumab (as the most widely studied drug) has been 
associated with a number of adverse effects, although dis-
continuation rates in anti-NGF trials are low [54]. Reported 
side-effects include paraesthesia, headaches, arthralgia, 
peripheral oedema, peripheral neuropathy, hypo- and 
hyper- aesthesia. Lower doses of tanezumab are associated 
with fewer adverse events [54]. Arthralgia was the most 
commonly reported side effect (8% of tanezumab-treated 
patients).
Fasinumab
Fasinumab is also a humanised monoclonal antibody devel-
oped by Regeneron and Teva with high specificity and 
affinity for NGF. It was recently investigated in a phase IIb/
III double‐blind, placebo‐controlled, randomised clinical 
trial of 421 patients with moderate-to-severe knee or hip 
OA and inadequate response or intolerance to analgesics 
[59]. Patients were randomised to receive fasinumab 1 mg, 
3 mg, 6 mg, 9 mg or placebo every 4 weeks over 16 weeks 
with follow-up until week 36. 346 patients completed the 
study. Statistically and clinically significant improvements 
in WOMAC pain, WOMAC physical function subscale and 
patient global assessment scores were detected with all the 
doses of fasinumab compared to placebo at week 16. These 
improvements were not dose-dependent.
Rapidly progressive OA
Rapidly progressive OA (RPOA) is the most serious adverse 
event reported with the anti-NGF therapies, with the risk 
apparently dose-related [59, 60]. It is a painful condition 
diagnosed radiographically by rapid joint space narrowing 
and severe progressive atrophic bone [61]. Recent trials have 
used a maximal 5 mg dose of tanezumab as the RPOA risk 
is reduced and outweighed by its potential therapeutic ben-
efit [62]. Although a higher rate of RPOA is observed with 
tanezumab 2.5 mg and 5 mg compared to NSAID [63], the 
combination of tanezumab and NSAIDs appears to increase 
the risk of RPOA compared to tanezumab alone [62], and 
modern trials have also been designed to reduce concomitant 
NSAID use.
Summary
Anti-NGF antibodies have demonstrated symptomatic 
improvement in hip and knee OA. Higher doses increase 
the risk of developing RPOA. These agents may be the first 
new OA therapy to emerge in many years, though careful 
evaluation of benefit-risk will be required.
Immunomodulators
Injectable Corticosteroids
Intra-articular corticosteroids have been shown to be effec-
tive in reducing OA pain, although their effects are short 
lived with no associated benefit seen at 6 months [64]. A 
Cochrane review of 27 trials investigating intra-articular 
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corticosteroids in knee OA found an association with small 
to moderate improvement in function at up to 6 weeks, but 
no improvement beyond this timeframe [65]. Moderate to 
large heterogeneity between trials was also found.
Intra‑articular Triamcinolone Acetonide Extended Release
Given the reported short-term benefits of intra-articular 
corticosteroid, FX006, a triamcinolone acetonide extended 
release (TA-ER) formulation produced using microsphere 
technology, with the aim of giving prolonged benefits, was 
investigated in patients with knee OA. TA-ER at doses 
10 mg, 40 mg and 60 mg were compared in a phase IIa ran-
domised, double-blind, controlled, dose-finding trial [66]. 
228 patients with knee OA were followed up for 12 weeks 
post single intra-articular knee injection. There was a sig-
nificant improvement in mean daily pain intensity scores 
(the primary outcome measure) with TA-ER 40 mg versus 
immediate-release triamcinolone 40 mg at weeks 5–10; fur-
thermore, all WOMAC subscale scores were significantly 
improved with TA-ER 40  mg compared to immediate-
release triamcinolone at 8 weeks. No superiority was dem-
onstrated with TA-ER 10 mg and 60 mg versus immediate-
release triamcinolone 40 mg in improving mean daily pain 
intensity, although TA-ER 10 mg was significantly superior 
to immediate-release triamcinolone 40 mg in improving 
some secondary efficacy endpoints. Similar frequencies of 
adverse events (AEs) were reported between TA-ER and 
immediate-release triamcinolone.
TA-ER was compared to placebo in a further phase IIB 
study of 306 knee OA patients. The primary outcome of 
a significant improvement in average daily pain (ADP) 
intensity versus placebo at 12 weeks was not achieved; 
however, TA-ER 32 mg significantly improved ADP inten-
sity scores versus placebo at weeks 1–11 and at week 13 
[67]. More recently, a phase III, multicentre, double-
blinded, randomised, controlled trial comparing TA-ER 
32 mg to immediate-release triamcinolone 40 mg and 
placebo in 484 knee OA patients achieved its primary 
endpoint of a significant improvement in ADP intensity 
compared to placebo at 12 weeks [68]. TA-ER did not 
significantly improve ADP intensity over immediate-
release triamcinolone at 12 weeks; however, WOMAC 
pain, stiffness and physical function scores, and the Knee 
injury and Osteoarthritis Outcome Score (Quality of Life 
subdomain—KOOS-QOL) at 12 weeks were significantly 
improved with TA-ER 32 mg compared to both placebo 
and immediate-release triamcinolone. The differences with 
the active comparator seen when using different outcome 
measures suggests a greater responsiveness for the dis-
ease-specific, multi-item WOMAC tool over the ADP sin-
gle item question. As TA-ER has been shown to be more 
effective than placebo, it has been licensed by the FDA for 
managing OA-related knee pain. A further advantage of 
TA-ER’s mechanism of action is reduced systemic expo-
sure compared to immediate-release triamcinolone, due to 
its slower intra-articular release [69]. TA-ER 32 mg has 
been shown to have less effect on glycaemic control than 
standard triamcinolone 40 mg in type 2 diabetic patients 
[70].
Summary
Intramuscular and intra-articular steroid provides short-lived 
symptomatic benefit in OA. An extended release intra-artic-
ular steroid is now licensed in the USA.
Hydroxychloroquine
Hydroxychloroquine is routinely used in the management 
of rheumatoid arthritis synovitis and has also been used in 
the management of inflammatory hand OA, related to anec-
dotal evidence of benefit and a tolerable safety profile [71, 
72]. The immunomodulatory actions of hydroxychloroquine 
work through inhibitory effects on toll-like receptor (TLR) 
signalling [73]. This was considered potentially therapeutic 
in OA as TLRs are upregulated in OA cartilage tissue and 
trigger its breakdown via pro-inflammatory pathways [74, 
75]. Furthermore, there is evidence of synovitis in hand OA 
[76, 77]. Early small pilot studies suggested symptomatic 
improvement following hydroxychloroquine treatment [78, 
79]. A large randomised, double-blind, placebo-controlled 
clinical trial investigated this further in 248 patients over a 
12-month period [80]. Patients with moderate-to-severe hand 
pain were randomised to hydroxychloroquine or placebo, 
along with their usual analgesic medication. No significant 
reduction in hand pain with additional hydroxychloroquine 
compared to placebo at 6 months was detected, therefore 
not achieving primary endpoint. Hydroxychloroquine also 
did not slow radiographic OA progression compared to pla-
cebo at 12 months. A subset of patients who were stratified 
for (commonly found) ultrasound-detected synovitis also 
did not demonstrate hydroxychloroquine efficacy. Another 
randomised controlled trial compared hydroxychloroquine 
400 mg to placebo in 196 patients with hand OA (but not on 
concomitant NSAID or corticosteroid treatment) and did not 
detect a significant difference in pain scores after 24 weeks 
of treatment [81].
Summary
Latest evidence demonstrates hydroxychloroquine is ineffec-
tive in reducing patient symptoms in hand OA.
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Tumour Necrosis Factor Inhibitors
Evidence suggests that tumour necrosis factor alpha (TNF 
α) is implicated in OA pathogenesis [82]. However, studies 
of adalimumab have not shown it to be effective compared 
to placebo in reducing symptoms of hand OA [83, 84]. More 
recently, the HUMOR trial compared subcutaneous adali-
mumab 40 mg on alternative weeks versus placebo over 
12 weeks in a crossover-design study of 43 patients with 
erosive hand OA and synovitis seen on magnetic resonance 
imaging (MRI) [85]. There was an 8-week washout period 
before treatment groups crossed over. Adalimumab did not 
significantly reduce visual analogue scale (VAS) scores 
compared to placebo. In addition, there were no signifi-
cant differences detected for secondary outcome measures 
including change in MRI-detected synovitis and bone mar-
row lesions.
Another anti-TNF α agent, etanercept, was recently stud-
ied in a 1-year, double-blind, randomised, placebo-con-
trolled, multicentre trial of 90 patients with symptomatic 
erosive inflammatory hand OA. The primary endpoint of a 
significant improvement in VAS pain at 24 weeks was not 
achieved with etanercept 50 mg weekly [86]. In addition, 
there was no significant treatment reduction in ultrasono-
graphic or MRI-detected synovitis after 1 year. A signifi-
cant reduction in MRI-detected bone marrow lesions in the 
interphalangeal joints of one hand was detected after 1 year 
with etanercept; however, this was in a very small subgroup 
(n = 10 in each treatment group).
Summary
Anti-TNF agents have not demonstrated symptomatic 
improvement versus placebo in OA.
Interleukin‑1 α and β Inhibition
Interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) 
expression is increased within OA cartilage and synovial 
membrane [87, 88]. Raised IL-1 levels are also associated 
with increased expression of OA pathophysiology markers 
in affected fluids and tissue including catabolic enzymes, 
prostaglandins, nitric oxide and other markers [89]. Block-
age of the interleukin-1 receptor has been shown to slow the 
progression of OA in animal models [90–93].
Anakinra, a recombinant form of interleukin-1 receptor 
antagonist (IL-1Ra), was investigated in a randomised, mul-
ticentre, double-blind, placebo-controlled study of 170 knee 
OA patients who received a single intra-articular injection 
of placebo, anakinra 50 mg, or anakinra 150 mg in their 
symptomatic knee. No significant difference in the mean 
WOMAC pain score improvements from baseline to week 
4 could be detected between the treatment groups, although 
anakinra was well tolerated [94].
Lutikizumab (formerly ABT-981) is a novel human dual 
variabledomain immunoglobulin that targets and inhibits 
IL-1α and IL-1β [95]. This was investigated in the ILLUS-
TRATE-K trial, a randomised, double-blind, placebo-con-
trolled, parallel-group phase II study comparing fortnightly 
subcutaneous injections of lutikizumab at 25 mg, 100 mg, 
or 200 mg in patients with knee OA over 50 weeks [96]. 
The study achieved its primary endpoint with preliminary 
results demonstrating a significant improvement in WOMAC 
pain score at 16 weeks with lutikizumab 100 mg compared 
to placebo. However, there was no significant improvement 
with lutikizumab 25 mg or 200 mg compared to placebo at 
this time point. Cartilage thickness, MRI synovitis, and other 
structural endpoints were similar between lutikizumab and 
placebo, although lutikizumab was generally well tolerated. 
With the lack of dose response and failure to meet structural 
endpoints, there is uncertainty regarding the clinical efficacy 
of lutikizumab in knee OA based on this study.
Lutikizumab was also trialled in patients with erosive 
hand OA, in a phase IIa, placebo-controlled, randomised 
study. Clinical and radiological outcomes were measured in 
131 patients with hand OA as per ACR criteria (≥ 3 inflamed 
interphalangeal joints which are tender, swollen, or both, 
hand pain ≥ 6 (scale 0–10), and ≥ 1 erosive interphalangeal 
joint on X-ray). Subjects were given lutikizumab 200 mg 
(n = 67) or placebo (n = 64) every 2 weeks for 26 weeks. Pre-
liminary data did not demonstrate a significant improvement 
in Australian/Canadian Hand OA Index (AUSCAN) pain 
scores with lutikizumab compared to placebo at 16 weeks. 
There was also no significant difference in X-Ray or MRI 
data between treatment groups [97].
However, there have been further developments in the 
use of IL-1 in treating OA, involving canakinumab, a mono-
clonal antibody targeting IL-1β. Previous in vitro studies 
of canakinumab on human chondrocytes demonstrated 
increased proteoglycan and reduced nitric oxide synthe-
sis which may reduce cartilage breakdown [98]. Canaki-
numab was recently studied in the CANTOS trial: a very 
large randomised, placebo-controlled trial investigating the 
cardiovascular effect of subcutaneous canakinumab [99]. 
10,061 patients with previous myocardial infarction and a 
high-sensitivity C-reactive protein level ≥ 2 mg/L on blood 
testing were given canakinumab doses of 50 mg, 150 mg 
or 300 mg every 3 months for a median of 3.7 years. The 
study demonstrated that canakinumab at a dose of 150 mg 
was associated with a significantly lower rate of recurrent 
cardiovascular events compared to placebo, independent of 
lipid-level lowering. Despite this being primarily a cardio-
vascular study, a post hoc study reported reduced incidence 
of OA symptoms (reported as adverse events) and total knee 
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and hip replacements in the patients who received canaki-
numab [100]. The implications of these findings are unclear.
Summary
Although previous studies of IL-1 inhibition in OA did not 
demonstrate a symptomatic or structural benefit, recent anal-
yses from the CANTOS study suggest benefits in reducing 
joint replacement; more research in this area is required.
Methotrexate
Methotrexate has been investigated in a phase III trial of 
patients with knee OA, targeting the synovitis and associated 
pain in the condition [101]. 155 patients were randomised 
to receive methotrexate (dose escalating 10–25 mg over 
8 weeks with maintenance dose at 25 mg or the highest 
tolerated dose) or placebo. Preliminary data demonstrated 
statistically significant improvements with methotrexate at 
6 months for WOMAC stiffness and physical function, but 
not pain. This benefit was reduced at 12 months. As a sec-
ondary outcome measure, synovial volume was measured on 
MRI at baseline and 6 months with no significant difference 
between treatment groups.
Methotrexate has also been investigated in patients with 
erosive hand OA [102]. 64 patients were randomised to 
receive methotrexate 10 mg weekly or placebo. There was 
no significant difference between treatment groups in VAS 
pain score reduction at 3 months; therefore the study did not 
achieve its primary outcome. There was also no significant 
improvement in pain at 12 months; however, there appeared 
to be less structural progression in the methotrexate group, 
with more remodelling seen in erosive joints.
Summary
Usual dose methotrexate has demonstrated symptomatic 
improvement at 6 months in knee OAbut low dose has not 
been beneficial in hand OA. More consideration of metho-
trexate benefits are required as a potential analgesic therapy.
Conclusion
Treatment options for osteoarthritis pain remain limited. 
Different joint structures have been targeted in pharmaco-
logical intervention studies of OA with variable levels of 
success. Despite structural improvement with a cartilage 
anabolic agent and an osteoclast inhibitor, their effect on 
symptoms are still under investigation. The limitations in 
developing novel therapeutics in OA are partly related to our 
limited understanding of the structure–pain relationship in 
OA, resulting in a current lack of attractive tissue target in 
OA. However, recent trial data of agents targeting peripheral 
nociceptive pathways in knee OA have been promising.
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